1086423-57-5

Basic information

• Product Name: 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide
• Synonyms: 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide
• CAS NO: 1086423-57-5
• Molecular Weight: 593.586
• Mol File: 1086423-57-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide(CAS DataBase Reference)
• NIST Chemistry Reference: 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide(1086423-57-5)
• EPA Substance Registry System: 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide(1086423-57-5)

Safety Data

• Hazardous Substances Data: 1086423-57-5(Hazardous Substances Data)

Upstream product

• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1086423-56-4 7-(toluene-4-sulfonyl)-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid 
• 1086423-55-3 7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile 
• 1005206-16-5 7H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile 
• 23410-19-7 3-amino-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide 

Downstream Products

• 1086423-54-2 7H-pyrrolo[2,3-d]pyrimidine-4-carboxylic acid [2-methyl-5-(3-trifluoromethyl-phenylcarbamoyl)-phenyl]-amide 

Relevant articles and documents

PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF

The invention provides compounds of formula (l) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, CSK, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRalpha, PDGFRbeta, PKCalpha, SAPK2alpha, Src, SIK, Syk, Tie2 and TrkB kinases.